In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium

Microbial Drug Resistance

Volumn 12, Issue 1, 2006, Pages 1-6

  Danelishvili, Lia ^a,b   Young, Lowell S ^b   Bermudez, Luiz E ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b Kuzell Institute for Arthritis and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MONONUCLEAR PHAGOCYTE; MOUSE; MYCOBACTERIOPHAGE TM4; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; FEMALE; MICE; MICE, INBRED C57BL; MYCOBACTERIOPHAGES; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 33646025194     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2006.12.1     Document Type: Article

References (24)

1. Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky. 1998. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:5-15.
2. Anpilov, L.I., and A.A. Prokudin. 1984. [Preventive effectiveness of dried polyvalent Shigella bacteriophage in organized collective farms]. Voen Med Zh. 5:39-40.
3. Barrow, P.A., and J.S. Soothill. 1997. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5:268-271.
4. Bermudez, L.E., C.B. Inderlied, P. Kolonoski, M. Wu, L. Barbara-Burnham, and L.S. Young. 1996. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob. Agents Chemother. 40:546-551.
5. Biswas, B., S. Adhya, P. Washart, B. Paul, A.N. Trostel,B. Powell, R. Carlton, and C.R. Merril. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70:204-210.
6. Broxmeyer, L., D. Sosnowska, E. Miltner, O. Chacon, D. Wagner, J. McGarvey, R.G. Barletta, and L.E. Bermudez. 2002. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J. Infect. Dis. 186:1155-1160.
7. Carlton, R.M. 1999. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz). 47:267-274.
8. Cislo, M., M. Babrowski, B. Weber-Babrowska, and A. Woyton. 1987. Bacteriophage treatment of suppurative skin infections. Arch. Immunol. Ther. Exp. (Warsz). 35:175-183.
9. Cox, H.S., J.D. Orozco, R. Male, S. Ruesch-Gerdes, D. Falzon, I. Small, D. Doshetov, Y. Kebede, and M. Aziz. 2004. Multidrug-resistant tuberculosis in central Asia. Emerg. Infect. Dis. 10:865-872.
10. Foley-Thomas, E.M., D.L. Whipple, L.E. Bermudez, and R.G. Barletta. 1995. Phage infection, transfection and transformation of Mycobacterium avium complex and Mycobacterium paratuberculosis. Microbiology 141 (Pt 5):1173-1181.
11. Ioseliani, G.D., G.D. Meladze, N. Chkhetiia, M.G. Mebuke, and N. Kiknadze. 1980. [Use of bacteriophage and antibiotics for prevention of acute postoperative empyema in chronic suppurative lung diseases]. Grudn Khir. 6:63-67.
12. Jacobs, W.R., Jr., G.V. Kalpana, J.D. Cirillo, L. Pascopella, S.B. Snapper, R.A. Udani, W. Jones, R.G. Barletta, and B.R. Bloom. 1991. Genetic systems for mycobacteria. Methods Enzymol. 204:537-555.
13. Krueger, A.P., and E.J. Scribner. 1941. Bacteriophage therapy. II. The bacteriophage: its nature and its therapeutic use. J. Am. Med. Assn. 19:2160-2277.
14. Kwarcinski, W., B. Lazarkiewicz, B. Weber-Dabrowska, J. Rudnicki, K. Kaminski, and M. Sciebura. 1994. [Bacteriophage therapy in the treatment of recurrent subphrenic and subhepatic abscess with jejunal fistula after stomach resection]. Pol. Tyg. Lek. 49:535.
15. Meladze, G.D., M.G. Mebuke, N. Chkhetiia, N. Kiknadze, and G.G. Koguashvili. 1982. [Efficacy of staphylococcal bacteriophage in the treatment of purulent lung and pleural diseases]. Grudn Khir. 53-56.
16. Sakandelidze, V.M., and A.N. Meipariani. 1974. [Use of combined phages in suppurative-inflammatory diseases]. Zh. Mikrobiol. Epidemiol. Immunobiol. 51:135-136.
17. Schless, R.A. 1932. Staphylococcus aureus meningitis: treatment with specific bacteriophage. Am. J. Dis. Child. 44:813-822.
18. Smith, H.W., and M.B. Huggins. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
19. Smith, H.W., and M.B. Huggins. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129(Pt8):2659-2675.
20. Soothill, J.S., J.C. Lawrence, and G.A.J. Ayliffe. 1988. The efficacy of phages in the prevention of the destruction of pig skin in vitro by Pseudomonas aeruginosa. Med. Sci. Res. 16:1287-1288.
21. Soothill, J.S. 1994. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20:209-211.
22. Stroj, L., B. Weber-Dabrowska, K. Partyka, M. Mulczyk, and M. Wojcik. 1999. [Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn]. Neurol. Neurochir. Pol. 33:693-698.
23. Sula, L., J. Sulova, and M. Stolcpartova. 1981. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med. 4:209-214.
24. Zemskova, Z.S., and I.R. Dorozhkova. 1991. [Pathomorphological assessment of the therapeutic effect of mycobacteriophages in tuberculosis]. Probl. Tuberk. 11:63-66.